IL6 and non-small cell lung carcinoma: While baseline plasma concentrations were not associated with survival in another cohort of NSCLC patients (n = 47) treated with αPD‐1 agents, the change in plasma IL‐6 at an early timepoint during therapy compared with baseline was associated with PFS.32